Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$38.43 - $48.6 $527,759 - $667,423
-13,733 Reduced 47.2%
15,360 $675,000
Q1 2024

May 10, 2024

BUY
$43.78 - $63.86 $276,339 - $403,084
6,312 Added 27.71%
29,093 $1.46 Million
Q4 2023

Feb 13, 2024

BUY
$36.35 - $63.02 $412,936 - $715,907
11,360 Added 99.47%
22,781 $1.38 Million
Q3 2023

Nov 13, 2023

BUY
$48.35 - $61.26 $552,205 - $699,650
11,421 New
11,421 $650,000

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.92B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Center Book Partners LP Portfolio

Follow Center Book Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Center Book Partners LP with notifications on news.